How to actually get a GLP-1 covered by insurance: the 2026 playbook
Coverage is winnable more often than people think. The step-by-step process: confirm your formulary, document the comorbidity, navigate prior authorization, and appeal a denial.
By GLPZoom Editorial
2 min readUpdated
Jump to section
Insurance coverage for GLP-1 weight-loss drugs is patchy, but it's winnable far more often than the 'my insurance won't cover it' resignation suggests. The difference between a covered $25 copay and a $1,300 cash bill usually comes down to process, not luck. Here's the playbook.
Step 1: Confirm what your formulary actually says
Call the number on your insurance card and ask three precise questions: is Wegovy (or Zepbound) on the formulary; is it covered for weight management specifically (not just diabetes); and what tier is it. Many plans cover the diabetes label (Ozempic, Mounjaro) but exclude the weight-loss label, even though it's the same molecule. Get the answer in writing if you can.
Step 2: Document the medical criteria
FDA labels require BMI ≥30, or ≥27 with a weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes). Insurers mirror this. Before your visit, gather documentation of your BMI and any comorbidity, this is what the prior authorization will hinge on. If you have a qualifying condition, make sure it's in your chart.
Step 3: Navigate prior authorization
Most plans that cover GLP-1s require prior authorization (PA): your prescriber submits clinical justification, the insurer reviews. This is where a program with an insurance concierge earns its fee, they file the PA for you, which dramatically raises approval rates versus a self-filed request. Some plans also require step therapy (proving an older, cheaper drug failed first); ask whether that applies.
Step 4: Appeal a denial
A first-pass denial is not the end. You have the right to appeal, and a letter of medical necessity from your prescriber, citing your BMI, comorbidities, and prior treatment attempts, overturns a meaningful share of denials. If the internal appeal fails, most states offer an external review by an independent body. Persistence wins coverage that an initial 'no' would have cost you.
If coverage genuinely isn't available
When a plan flatly excludes anti-obesity drugs, pivot to manufacturer direct-pay (NovoCare, LillyDirect) or a flat-rate telehealth program rather than paying list price. Our insurance coverage matrix shows where major carriers stand, and our cost estimator maps your cheapest path if insurance is a dead end.
Related reads
Wegovy prior authorization: the step-by-step approval playbook (2026)
Wegovy denials usually come from incomplete documentation, not clinical ineligibility. Here's the exact step-by-step process that gets approval on the first submission, plus what to do when denied.
GLP-1 hair loss timeline: when it starts, peaks, and recovers (2026)
Hair shedding on Wegovy, Ozempic, or Zepbound follows a predictable pattern tied to rapid weight loss, not the drug itself. Here's the week-by-week timeline, why it happens, and what actually shortens recovery.
Wegovy vs Ozempic in 2026: same drug, different prescribing rules
Wegovy and Ozempic are both semaglutide. Wegovy is FDA-approved for weight management; Ozempic for type 2 diabetes. Same active ingredient — but different dose, different insurance pathway, different cost, and different clinical conversation. Here's the full comparison.